Literature DB >> 18285668

Effectiveness of oseltamivir treatment among children with influenza A or B virus infections during four successive winters in Niigata City, Japan.

Maki Sato1, Reiko Saito, Isamu Sato, Naohito Tanabe, Yugo Shobugawa, Asami Sasaki, Danjuan Li, Yasushi Suzuki, Mizuho Sato, Takatsugu Sakai, Taeko Oguma, Hiroki Tsukada, Fumitake Gejyo, Hiroshi Suzuki.   

Abstract

Oseltamivir has been used for treatment of influenza A and B infections, but recent reports documented that it was less active against the latter. We compared the effectiveness of oseltamivir in children between laboratory confirmed influenza A and B over 4 influenza seasons from 2001 to 2005 in a pediatric clinic in Japan. Among 1,848 patients screened, 299 influenza A and 209 influenza B patients were administered oseltamivir (treated groups), and 28 influenza A and 66 influenza B patients were assigned as non-treated groups. The duration of fever, defined as period when patients had the maximum temperature higher than 37.5 degrees C in three-time measurements in a day after the clinic visit, was evaluated among the four groups. In uni-variate analysis, the duration of fever was shorter for treated group than non-treated for influenza A (1.8 +/- 0.9 days vs 2.6 +/- 1.3 days, p < 0.01), but it was not significant for influenza B (2.4 +/- 1.3 days vs 2.8 +/- 1.2 days, p = 0.9). The fever duration was longer in treated influenza B than A patients (p < 0.01). Multi-variate analysis indicated younger age (< 6 years old) and higher body temperature at the clinic visit prolonged the duration of fever. Adjusted average duration of fever indicated that oseltamivir was effective for both types, but more effective on influenza A, and the benefit increased for younger children. Our data provide evidence that oseltamivir is beneficial for influenza infections, but the effectiveness is differed by type and age.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18285668     DOI: 10.1620/tjem.214.113

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  19 in total

Review 1.  Antivirals for influenza: a summary of a systematic review and meta-analysis of observational studies.

Authors:  Nancy Santesso; Jonathan Hsu; Reem Mustafa; Jan Brozek; Yao Long Chen; Jessica P Hopkins; Adrienne Cheung; Gayane Hovhannisyan; Liudmila Ivanova; Signe A Flottorp; Ingvil Saeterdal; Arthur D Wong; Jinhui Tian; Timothy M Uyeki; Elie A Akl; Pablo Alonso-Coello; Fiona Smaill; Holger J Schünemann
Journal:  Influenza Other Respir Viruses       Date:  2013-09       Impact factor: 4.380

Review 2.  Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance.

Authors:  Andrew J Burnham; Tatiana Baranovich; Elena A Govorkova
Journal:  Antiviral Res       Date:  2013-09-04       Impact factor: 5.970

Review 3.  The burden of influenza B: a structured literature review.

Authors:  W Paul Glezen; Jordana K Schmier; Carrie M Kuehn; Kellie J Ryan; John Oxford
Journal:  Am J Public Health       Date:  2013-01-17       Impact factor: 9.308

Review 4.  Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies.

Authors:  Jonathan Hsu; Nancy Santesso; Reem Mustafa; Jan Brozek; Yao Long Chen; Jessica P Hopkins; Adrienne Cheung; Gayane Hovhannisyan; Liudmila Ivanova; Signe A Flottorp; Ingvil Saeterdal; Arthur D Wong; Jinhui Tian; Timothy M Uyeki; Elie A Akl; Pablo Alonso-Coello; Fiona Smaill; Holger J Schünemann
Journal:  Ann Intern Med       Date:  2012-02-27       Impact factor: 25.391

5.  Monoclonal Antibody Therapy Protects Pharmacologically Immunosuppressed Mice from Lethal Infection with Influenza B Virus.

Authors:  Bindumadhav M Marathe; Guha Asthagiri Arunkumar; Peter Vogel; Philippe Noriel Q Pascua; Jeremy Jones; Richard J Webby; Florian Krammer; Elena A Govorkova
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

Review 6.  Amantadine and rimantadine for influenza A in children and the elderly.

Authors:  Márcia G Alves Galvão; Marilene Augusta Rocha Crispino Santos; Antonio J L Alves da Cunha
Journal:  Cochrane Database Syst Rev       Date:  2014-11-21

7.  Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Scott A Harper; John S Bradley; Janet A Englund; Thomas M File; Stefan Gravenstein; Frederick G Hayden; Allison J McGeer; Kathleen M Neuzil; Andrew T Pavia; Michael L Tapper; Timothy M Uyeki; Richard K Zimmerman
Journal:  Clin Infect Dis       Date:  2009-04-15       Impact factor: 9.079

8.  Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective.

Authors:  Margaret Okomo-Adhiambo; Katrina Sleeman; Kristina Ballenger; Ha T Nguyen; Vasiliy P Mishin; Tiffany G Sheu; James Smagala; Yan Li; Alexander I Klimov; Larisa V Gubareva
Journal:  Viruses       Date:  2010-10-13       Impact factor: 5.818

9.  The association between influenza treatment and hospitalization-associated outcomes among Korean children with laboratory-confirmed influenza.

Authors:  Jacqueline K Lim; Tae Hee Kim; Paul E Kilgore; Allison E Aiello; Byung Min Choi; Kwang Chul Lee; Kee Hwan Yoo; Young-Hwan Song; Yun-Kyung Kim
Journal:  J Korean Med Sci       Date:  2014-04-01       Impact factor: 2.153

10.  Human Antibodies Targeting Influenza B Virus Neuraminidase Active Site Are Broadly Protective.

Authors:  Anders Madsen; Ya-Nan Dai; Meagan McMahon; Aaron J Schmitz; Jackson S Turner; Jessica Tan; Tingting Lei; Wafaa B Alsoussi; Shirin Strohmeier; Mostafa Amor; Bassem M Mohammed; Philip A Mudd; Viviana Simon; Rebecca J Cox; Daved H Fremont; Florian Krammer; Ali H Ellebedy
Journal:  Immunity       Date:  2020-09-24       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.